Carrie O'Connor Selected Research

Nucleotides

1/2022	Targeted therapy of pyrrolo[2,3-d]pyrimidine antifolates in a syngeneic mouse model of high grade serous ovarian cancer and the impact on the tumor microenvironment.
1/2021	Discovery of 6-substituted thieno[2,3-d]pyrimidine analogs as dual inhibitors of glycinamide ribonucleotide formyltransferase and 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase in de novo purine nucleotide biosynthesis in folate receptor expressing human tumors.
12/2019	Discovery of amide-bridged pyrrolo[2,3-d]pyrimidines as tumor targeted classical antifolates with selective uptake by folate receptor α and inhibition of de novo purine nucleotide biosynthesis.
10/2018	Fluorine-Substituted Pyrrolo[2,3- d]Pyrimidine Analogues with Tumor Targeting via Cellular Uptake by Folate Receptor α and the Proton-Coupled Folate Transporter and Inhibition of de Novo Purine Nucleotide Biosynthesis.
1/2018	Tumor Targeting with Novel Pyridyl 6-Substituted Pyrrolo[2,3- d]Pyrimidine Antifolates via Cellular Uptake by Folate Receptor α and the Proton-Coupled Folate Transporter and Inhibition of De Novo Purine Nucleotide Biosynthesis.
1/2016	Tumor Targeting with Novel 6-Substituted Pyrrolo [2,3-d] Pyrimidine Antifolates with Heteroatom Bridge Substitutions via Cellular Uptake by Folate Receptor α and the Proton-Coupled Folate Transporter and Inhibition of de Novo Purine Nucleotide Biosynthesis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Carrie O'Connor Research Topics

Disease

14	Neoplasms (Cancer) 12/2023 - 09/2015
3	Ovarian Epithelial Carcinoma 02/2024 - 01/2017
2	Ovarian Neoplasms (Ovarian Cancer) 02/2024 - 01/2022
1	Adenocarcinoma 01/2020
1	Pancreatic Neoplasms (Pancreatic Cancer) 01/2020

Drug/Important Bio-Agent (IBA)

11	Folic Acid (Vitamin M)FDA LinkGeneric 12/2023 - 09/2015
10	Folic Acid AntagonistsIBA 12/2023 - 09/2015
10	pyrimidineIBA 12/2023 - 09/2015
8	Proton-Coupled Folate TransporterIBA 12/2023 - 09/2015
8	purineIBA 12/2023 - 01/2016
6	Reduced Folate Carrier ProteinIBA 12/2023 - 09/2015
6	NucleotidesIBA 01/2022 - 01/2016
5	CarbonIBA 02/2024 - 01/2020
4	Hydroxymethyl and Formyl TransferasesIBA 02/2024 - 01/2018
3	Pemetrexed (MTA)FDA Link 12/2023 - 01/2020
3	glycinamide ribonucleotideIBA 01/2021 - 01/2018
2	Cisplatin (Platino)FDA LinkGeneric 02/2024 - 01/2017
2	RibonucleotidesIBA 01/2021 - 01/2020
2	EnzymesIBA 01/2021 - 10/2019
2	Methotrexate (Mexate)FDA LinkGeneric 01/2021 - 01/2020
2	Glycine Hydroxymethyltransferase (Serine Hydroxymethyltransferase)IBA 01/2020 - 10/2019
1	Tetrahydrofolate Dehydrogenase (Dihydrofolate Reductase)IBA 02/2024
1	Serine (L-Serine)FDA Link 02/2024
1	furanIBA 01/2021
1	N(alpha)- (4- amino- 4- deoxypteroyl)- N(delta)- hemiphthaloyl- L- ornithine (PT 523)IBA 01/2021
1	ThiophenesIBA 01/2021
1	S 6 (S-6)IBA 01/2020
1	Aligeron (AS 2)IBA 01/2020
1	SulfurIBA 01/2020
1	PyrimidinesIBA 12/2019
1	AmidesIBA 12/2019
1	NAD (NADH)IBA 10/2019
1	Glycine (Aminoacetic Acid)FDA LinkGeneric 10/2019
1	Adenosine Triphosphate (ATP)IBA 10/2019
1	FluorineIBA 10/2018

Therapy/Procedure

3	Therapeutics 12/2023 - 01/2021